Acorda Therapeutics (ACOR) Moving On Heavy Pre-Market Trading

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Acorda Therapeutics ( ACOR) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Acorda Therapeutics as such a stock due to the following factors:

  • ACOR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $13.3 million.
  • ACOR traded 93,700 shares today in the pre-market hours as of 8:03 AM, representing 21.2% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ACOR with the Ticky from Trade-Ideas. See the FREE profile for ACOR NOW at Trade-Ideas

More details on ACOR:

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States. ACOR has a PE ratio of 66.7. Currently there are 2 analysts that rate Acorda Therapeutics a buy, no analysts rate it a sell, and 4 rate it a hold.

The average volume for Acorda Therapeutics has been 448,000 shares per day over the past 30 days. Acorda has a market cap of $1.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 1.90 and a short float of 9.5% with 10.66 days to cover. Shares are up 0.2% year-to-date as of the close of trading on Monday.

If you liked this article you might like

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Stiff-Arms Investor's Demand for Sale

Biotech Movers: Adamis Shares Jump After FDA Approves Epinephrine Pre-filled Syringe